Benign prostatic hyperplasia (BPH) often produces chronic and progressive lower urinary tract symptoms or complications as bladder stone, leading many men to seek treatment. Prostatic enlargement due to BPH rarely exceeds 100 g, which occurs in only 4% of men over 70 years of age [1] .Giant BPH is arbitrarily defined as specimens over 200 g[2] or 500 g [3] ;the lower threshold was suggested by ...

Human papillomavirus, type 16 (HPV-16) and type 18 (HPV-1 8) are known to play a role in the development of neoplastic disorders of the urogenital organs. The presence of HPV-1 6 and HPV18 in prostatic tissue with benign hyperplasia has been a matter of controversy. Some investigators have reported a high prevalence of HPV-16 DNA and a low prevalence of HPV-18 DNA in prostatic tissue,'-3 while ...

A PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF A SINGLE TREATMENT OF 100 U, 200 U, or 300 U BOTOX® COMPARED WITH PLACEBO INJECTED INTO THE PROSTATE TO TREAT LOWER URINARY TRACT SYMPTOMS (LUTS) IN PATIENTS DUE TO BENIGN PROSTATIC HYPERPLASIA Trial ID: 191622-517-05 Coordination: CMX Research Inc. Trial design: A phase II study assessing the safety and effi cacy of a single treatment of BO...

The development of human benign or malignant prostatic diseases is closely associated with androgens, primarily testosterone (T) and dihydrotestosterone (DHT). T is converted to DHT by 5-alpha reductase (5-AR) isozymes. Differential expression of 5-AR isozymes is observed in both human benign and malignant prostatic tissues. 5-AR inhibitors (5-ARI) are commonly used for the treatment of benign ...

We studied arginase activity in human prostatic tissue in 15 patients with benign hyperplasia and 27 patients with prostatic carcinoma. Arginase specific activity is greater (p less than 0.0001) in prostatic carcinomas than in hyperplastic prostates. Arginase specific activity is correlated inversely (p less than 0.0001) with the histological grade of the tumor.

Purpose To evaluate the efficacy and safety of a minimally invasive treatment for benign prostatic hyperplasia (BPH) by transurethral dehydrated ethanol injection. Patients and method Eight patients with clinical symptoms of benign prostatic hyperplasia were evaluated by urodynamic study, cystoscope and transrectal ultrasound preoperatively. Under regional anesthesia, transurethral injection wa...

LUTS, lower urinary tract symptoms QoL, quality of life; QoL can be regarded as covering bothersomeness, impact on quality of life, and sexual functioning BPH, benign prostatic hyperplasia; this term is reserved for the characteristic histological changes associated with BPH BPE, benign prostatic enlargement; this term refers to documented enlargement of the gland BPO, benign prostatic obstruct...

benign prostatic hyperplasia generally affects males above fourty years of age and has significant effect in overall quality of life (qol). this is one of the cause of millions of dollors in healthcare expenditure. alpha one adrenoreceptor blockers are frequently used for the benign prostatic enlargement because of their significant effect on storage and voiding symptoms, qol, flow rate and pos...